Singapore, Oct. 27 -- The Health Sciences Authority received information related to the study titled 'GC-LTFU-001: Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells'. The fo... Read More
Singapore, Oct. 27 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Saf... Read More
Singapore, Oct. 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants wit... Read More
U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07895953) titled 'Predictors of Success and Failure of v-NOTES Hysterectomy for Large and Very Large Uteri' o... Read More
Singapore, Oct. 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficac... Read More
Singapore, Oct. 27 -- The Health Sciences Authority received information related to the study titled 'FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy o... Read More
Singapore, Oct. 27 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with Beva... Read More
U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07895056) titled 'A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-70... Read More
Singapore, Oct. 27 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Ver... Read More
Singapore, Oct. 27 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy... Read More